Merck & Co. Inc. stock surges on Terns Pharmaceuticals acquisition and Dow Jones momentum amid market peace hopes

Merck & Co. Inc. stock rallied sharply as the company announced its intent to acquire Terns Pharmaceuticals, Inc., a move set to expand its hematology pipeline with the novel candidate TERN-701 targeting chronic myeloid leukemia (CML). The Merck & Co. Inc. stock was last seen on NYSE at 119.37 USD, up 2.58% in recent trading, contributing to a broader Dow Jones Industrial Average advance of 0.66% to 46,428.57 points on March 25, 2026. This development comes amid market hopes for geopolitical de-escalation easing oil and supply chain pressures, positioning Merck as a defensive yet growth-oriented play for US investors seeking stability in pharma.

As of: 26.03.2026

Dr. Elena Vasquez, Senior Pharma Equity Strategist: Merck's pipeline bolt-on via Terns underscores a strategic pivot in hematology, vital for US investors navigating oncology patent cliffs ahead.

Acquisition Details: Terns Deal Bolsters Hematology Focus

Merck & Co. Inc. is pursuing the full acquisition of Terns Pharmaceuticals, Inc., aiming to integrate TERN-701, a promising therapy for CML patients. This candidate represents a novel approach in treating this blood cancer, addressing unmet needs in resistant or intolerant cases. The deal expands Merck's oncology portfolio at a time when its blockbuster Keytruda faces looming patent expiry concerns post-2028.

The transaction highlights Merck's strategy to in-license or acquire assets that complement its internal R&D. Terns' pipeline, particularly TERN-701, has shown encouraging early data in preclinical and clinical stages, positioning it for potential fast-track development. For the Merck & Co. Inc. stock on NYSE, this news catalyzed the 2.58% gain to 119.37 USD, reflecting investor approval of proactive pipeline building.

Market reaction was swift, with shares outperforming the Dow Jones amid rotation into quality defensives. Analysts note the acquisition could add long-term revenue streams, diversifying from immuno-oncology dominance. US investors benefit from Merck's scale in executing such deals efficiently through its global infrastructure.

Dow Jones Context: Peace Hopes Lift Merck Amid Sector Rotation

The Dow Jones closed up 304.51 points or 0.66% at 46,428.57, with Merck & Co. Inc. stock leading gainers alongside Sherwin-Williams and Amazon. Friedenshoffnung – hopes for peace – drove optimism, potentially easing oil prices and supply chains, benefiting cyclicals but also defensives like pharma. Merck's 2.58% rise to 119.37 USD on NYSE exemplified this blend of stability and value.

Investors rotated into names offering resilience amid uncertainty. Merck combined defensive qualities with attractive valuations post-recent rotations. The stock's performance signals confidence in its ability to weather macroeconomic volatility while pursuing growth via acquisitions like Terns.

Strategic Fit: Enhancing Oncology Beyond Keytruda

Merck's acquisition targets CML, a niche within hematology where competition is less intense than in solid tumors. TERN-701's mechanism offers differentiation, potentially capturing market share from existing tyrosine kinase inhibitors. This fits Merck's broader push into precision medicine and rare diseases.

The company has a track record of successful integrations, from Keytruda's rise to recent animal health spinoffs. For US investors, this deal underscores Merck's R&D firepower, with over $10 billion annual spend fueling a robust late-stage pipeline. The Merck & Co. Inc. stock's valuation reflects this, trading at reasonable multiples relative to peers.

Pipeline diversification mitigates Keytruda cliff risks, where US sales exceed $20 billion annually. Terns adds early but high-potential assets, aligning with FDA priorities for orphan drugs. Investors see this as a low-risk bet on Merck's execution prowess.

US Investor Relevance: Domestic Pipeline and Market Leadership

US investors hold the lion's share of Merck & Co. Inc. stock, given its NYSE listing and blue-chip status in 401(k)s and pensions. The Terns deal directly impacts American patients, as CML affects thousands domestically, with high reimbursement potential under Medicare and private plans. Merck's US-centric revenue, over 50% from domestic sales, amplifies the importance.

Amid biotech M&A resurgence, Merck acts as a consolidator, acquiring at premiums that signal confidence. This benefits shareholders through earnings accretion over time. The stock's dividend yield, consistently above 2%, appeals to income-focused US portfolios seeking pharma exposure without startup risks.

Geopolitical tailwinds from peace hopes reduce input costs for Merck's manufacturing, enhancing margins. US investors should monitor Q1 earnings for deal updates, as integration could accelerate Phase 2 trials stateside.

Risks and Open Questions: Integration Challenges Ahead

While promising, the Terns acquisition carries execution risks, including regulatory hurdles from FTC scrutiny on pharma deals. TERN-701's clinical success is not guaranteed, with historical failure rates in hematology exceeding 50%. Dilution from cash or stock payments could pressure near-term earnings.

Broader market risks include policy shifts under new administrations affecting drug pricing, like IRA negotiations. Keytruda competition from biosimilars looms larger. Investors must weigh if 119.37 USD on NYSE embeds too much optimism for unproven assets.

Supply chain stabilization from peace hopes remains tentative; renewed tensions could reverse Dow gains. Merck's beta under 1 offers downside protection, but sector peers like Pfizer face similar headwinds.

Outlook: Positioning for Long-Term Growth

Merck & Co. Inc. stock eyes further upside if Terns integration succeeds, potentially valuing the asset at hundreds of millions in peak sales. Combined with Dow momentum, shares could test recent highs. US investors gain from Merck's dividend aristocrat status and buyback programs supporting returns.

Monitor upcoming milestones: deal close expected mid-2026, initial TERN-701 data in H2. Valuation metrics suggest room for expansion if macro improves. Defensive positioning makes Merck a core holding amid volatility.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.